Genetic signature of adult gliomas and correlation with MRI features

Expert Review of Molecular Diagnostics

Volumn 9, Issue 7, 2009, Pages 709-720

  Bruzzone, Maria Grazia ^a   Eoli, Marica ^a   Cuccarini, Valeria ^a   Grisoli, Marina ^a   Valletta, Lorella ^a   Finocchiaro, Gaetano ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

EGF receptor amplification; Genetic marker; Glioma; Loss of heterozygosity; Methylation; MRI; Mutation; Prognosis

Indexed keywords

ERLOTINIB; GEFITINIB; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADULT DISEASE; ASTROCYTOMA; CANCER GENETICS; CANCER GRADING; CANCER PATIENT; CHROMOSOME 10Q; CHROMOSOME 17P; CHROMOSOME 19Q; CHROMOSOME 1P; CLINICAL FEATURE; CLINICAL TRIAL; FOLLOW UP; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENOMICS; GLIOBLASTOMA; GLIOMA; HETEROZYGOSITY LOSS; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; TECHNOLOGY;

ADULT; BRAIN NEOPLASMS; DNA METHYLATION; GLIOMA; HUMANS; LOSS OF HETEROZYGOSITY; MAGNETIC RESONANCE IMAGING;

EID: 70350049243     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.09.44     Document Type: Review

References (67)

1. Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114(2), 97-109 (2007).
2. Kros JM. From expert opinion to evidence-based: changes in the gold standard of primary brain tumour diagnosis. J. Pathol. 213(1), 1-3 (2007).
3. Reddy SP, Britto R, Vinnakota K et al. Novel glioblastoma markers with diagnostic and prognostic value identified through transcriptome analysis. Clin. Cancer Res. 14(10), 2978-2987 (2008).
4. Yip S, Iafrate AJ, Louis DN. Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers. J. Neuropathol. Exp. Neurol. 67(1), 1-15 (2008).
5. Wager M, Menei P, Guilhot J et al. Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study. Br. J. Cancer 98(11), 1830-1838 (2008).
6. Kubota T, Yamada K, Kizu O et al. Relationship between contrast enhancement on fluid-attenuated inversion recovery MR sequences and signal intensity on T2-weighted MR images: visual evaluation of brain tumors. J. Magn. Reson. Imaging 21(6), 694-700 (2005). (Pubitemid 40770860)
7. Emblem KE, Nedregaard B, Nome T et al. Glioma grading by using histogram analysis of blood volume heterogeneity from MR-derived cerebral blood volume maps. Radiology 247(3), 808-817 (2008).
8. Van Meter T, Dumur C, Hafez N, Garrett C, Fillmore H, Broaddus WC. Microarray analysis of MRI-defined tissue samples in glioblastoma reveals differences in regional expression of therapeutic targets. Diagn. Mol. Pathol. 15(4), 195-205 (2006). (Pubitemid 44813658)
9. Earnest Ft, Kelly PJ, Scheithauer BW et al. Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 166(3), 823-827 (1988).
10. Carlson MR, Pope WB, Horvath S et al. Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clin. Cancer Res. 13(9), 2592-2598 (2007). (Pubitemid 46788024)
11. Aghi M, Gaviani P, Henson JW, Batchelor TT, Louis DN, Barker FG 2nd. Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin. Cancer Res. 11(24 Pt 1), 8600-8605 (2005). • Describes important MRI features associated to a key genetic marker and potential therapeutic target of glioblastoma multiforme (GBM). (Pubitemid 43005906)
12. Nelson SJ, Cha S. Imaging glioblastoma multiforme. Cancer J. 9(2), 134-145 (2003).
13. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J. Pathol. 170(5), 1445-1453 (2007). •• Exhaustive review on differences in GBM of relevant clinical impact. (Pubitemid 47339290)
14. Ohgaki H. Genetic pathways to glioblastomas. Neuropathology 25(1), 1-7 (2005).
15. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J. Neuropathol. Exp. Neurol. 64(6), 479-489 (2005). (Pubitemid 40781150)
16. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 6(3), 217-223; discussion 223-1214 (1996). • Landmark paper on genetic differences in GBM. (Pubitemid 26246377)
17. Yoshimoto K, Dang J, Zhu S et al. Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clin. Cancer Res. 14(2), 488-493 (2008). (Pubitemid 351226117)
18. Shinojima N, Tada K, Shiraishi S et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 63(20), 6962-6970 (2003). (Pubitemid 37322983)
19. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Bigner DD. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin. Immunol. 20(5), 267-275 (2008).
20. Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353(19), 2012-2024 (2005). (Pubitemid 41609094)
21. Haas-Kogan DA, Prados MD, Tihan T et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl Cancer Inst. 97(12), 880-887 (2005). (Pubitemid 41417939)
22. van den Bent MJ, Brandes AA, Rampling R et al. Randomized Phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J. Clin. Oncol. 27(8), 1268-1274 (2009).
23. Nutt CL, Mani DR, Betensky RA et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 63(7), 1602-1607 (2003).
24. 6- methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J. Clin. Oncol. 26(25), 4189-4199 (2008). • Review on O6-methylguanine methyltransferase (MGMT) - currently a major marker in GBM.
25. Zawlik I, Vaccarella S, Kita D, Mittelbronn M, Franceschi S, Ohgaki H. Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study. Neuroepidemiology 32(1), 21-29 (2009).
26. 6- methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin. Cancer Res. 13(9), 2606-2613 (2007). • Shows a significant correlation between MRI and MGMT methylation in primary and secondary GBM.
27. Brandes AA, Tosoni A, Franceschi E et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. J. Clin. Oncol. 27(8), 1275-1279 (2009).
28. Montanini L, Regna-Gladin C, Eoli M et al. Instability of mitochondrial DNA and MRI and clinical correlations in malignant gliomas. J. Neurooncol. 74(1), 87-89 (2005). (Pubitemid 41194536)
29. Diehn M, Nardini C, Wang DS et al. Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc. Natl Acad. Sci. USA 105(13), 5213-5218 (2008). •• Proposes that intratumoral heterogeneity of different gene-expression programs can be spatially resolved by imaging. (Pubitemid 351738536)
30. Pope WB, Chen JH, Dong J et al. Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. Radiology 249(1), 268-277 (2008).
31. Daumas-Duport C, Beuvon F, Varlet P, Fallet-Bianco C. [Gliomas: WHO and Sainte-Anne Hospital classifications]. Ann. Pathol. 20(5), 413-428 (2000).
32. Fallon KB, Palmer CA, Roth KA et al. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J. Neuropathol. Exp. Neurol. 63(4), 314-322 (2004).
33. Hoang-Xuan K, He J, Huguet S et al. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology 57(7), 1278-1281 (2001). (Pubitemid 32947388)
34. Blesa D, Mollejo M, Ruano Y et al. Novel genomic alterations and mechanisms associated with tumor progression in oligodendroglioma and mixed oligoastrocytoma. J. Neuropathol. Exp. Neurol. 68(3), 274-285 (2009).
35. Mariani L, Deiana G, Vassella E et al. Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy. J. Clin. Oncol. 24(29), 4758-4763 (2006). (Pubitemid 46630940)
36. Eoli M, Bissola L, Bruzzone MG et al. Reclassification of oligoastrocytomas by loss of heterozygosity studies. Int. J. Cancer 119(1), 84-90 (2006). • Demonstrates the power of genetic analysis in complementing the histological diagnosis of mixed gliomas.
37. Felsberg J, Erkwoh A, Sabel MC et al. Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol. 14(2), 121-130 (2004). (Pubitemid 38656383)
38. Jenkins RB, Blair H, Ballman KV et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 66(20), 9852-9861 (2006). (Pubitemid 44672036)
39. Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin. Cancer Res. 11(3), 1119-1128 (2005). (Pubitemid 40175761)
40. Alonso ME, Bello MJ, Arjona D et al. Mutational study of the 1p located genes p18ink4c, Patched-2, RIZ1 and KIF1B in oligodendrogliomas. Oncol. Rep. 13(3), 539-542 (2005).
41. Bagchi A, Papazoglu C, Wu Y et al. CHD5 is a tumor suppressor at human 1p36. Cell 128(3), 459-475 (2007). (Pubitemid 46198889)
42. Riemenschneider MJ, Reifenberger J, Reifenberger G. Frequent biallelic inactivation and transcriptional silencing of the DIRAS3 gene at 1p31 in oligodendroglial tumors with 1p loss. Int. J. Cancer 122(11), 2503-2510 (2008). (Pubitemid 351590483)
43. Ngo TT, Peng T, Liang XJ et al. The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. J. Natl Cancer Inst. 99(8), 639-652 (2007). (Pubitemid 47073545)
44. Mollemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int. J. Cancer 113(3), 379-385 (2005). (Pubitemid 40038704)
45. Megyesi JF, Kachur E, Lee DH et al. Imaging correlates of molecular signatures in oligodendrogliomas. Clin. Cancer Res. 10(13), 4303-4306 (2004). (Pubitemid 38878867)
46. Koeller KK, Rushing EJ. From the archives of the afip: oligodendroglioma and its variants: radiologic - pathologic correlation. Radiographics 25(6), 1669-1688 (2005).
47. Ricard D, Kaloshi G, Amiel-Benouaich A et al. Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann. Neurol. 61(5), 484-490 (2007). (Pubitemid 46878776)
48. Merrell R, Nabors LB, Perry A, Palmer CA. 1p/19q chromosome deletions in metastatic oligodendroglioma. J. Neurooncol. 80(2), 203-207 (2006). (Pubitemid 44614804)
49. Perry A, Fuller CE, Banerjee R, Brat DJ, Scheithauer BW. Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics. Front. Biosci. 8, A1-A9 (2003). (Pubitemid 39069937)
50. Law M, Brodsky JE, Babb J et al. High cerebral blood volume in human gliomas predicts deletion of chromosome 1p: Preliminary results of molecular studies in gliomas with elevated perfusion. J. Magn. Reson. Imaging 25(6), 1113-1119 (2007). (Pubitemid 46870266)
51. Brown R, Zlatescu M, Sijben A et al. The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma. Clin. Cancer Res. 14(8), 2357-2362 (2008). (Pubitemid 351551068)
52. Kapoor GS, Gocke TA, Chawla S et al. Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status. J. Neurooncol. 92(3), 373-386 (2009).
53. Watanabe K, Sato K, Biernat W et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin. Cancer Res. 3(4), 523-530 (1997). (Pubitemid 27211828)
54. Stander M, Peraud A, Leroch B, Kreth FW. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization grade II astrocytoma or oligoastrocytoma: a long-term analysis. Cancer 101(5), 1028-1035 (2004). (Pubitemid 39100437)
55. Gaiser T, Becker MR, Meyer J, Habel A, Siegelin MD. p53-mediated inhibition of angiogenesis in diffuse low-grade astrocytomas. Neurochem. Int. 54(7), 458-463 (2009).
56. Ware ML, Hirose Y, Scheithauer BW et al. Genetic aberrations in gliomatosis cerebri. Neurosurgery 60(1), 150-158; discussion 158 (2007).
57. Stevenson CB, Ehtesham M, McMillan KM et al. CXCR4 expression is elevated in glioblastoma multiforme and correlates with an increase in intensity and extent of peritumoral T2-weighted magnetic resonance imaging signal abnormalities. Neurosurgery 63(3), 560-569; discussion 569-570 (2008).
58. 6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression-free survival in patients with low-grade diffuse astrocytomas. Brain Pathol. 13(2), 176-184 (2003).
59. 6-methylguanine-DNA methyltransferase expression in supratentorial diffuse low-grade astrocytoma. Surg. Neurol. 68(6), 603-608; discussion 608-609 (2007).
60. Nakamura M, Watanabe T, Yonekawa Y, Kleihues P, Ohgaki H. Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C → A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 22(10), 1715-1719 (2001). (Pubitemid 32952152)
61. Parsons DW, Jones S, Zhang X et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897), 1807-1812 (2008). •• Landmark study reporting an integrated analysis of the GBM cancer genome, including expression analysis.
62. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 116(6), 597-602 (2008).
63. Ichimura K, Pearson DM, Kocialkowski S et al. IDH1 mutations are present in the majority of common adult gliomas but are rare in primary glioblastomas. Neuro. Oncol. 11(4), 341-347 (2009) .
64. Yan H, Parsons DW, Jin G et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360(8), 765-773 (2009). • Critical paper on the frequency and functional consequences of IDH mutations in gliomas.
65. Jasanoff A. MRI contrast agents for functional molecular imaging of brain activity. Curr. Opin. Neurobiol. 17(5), 593-600 (2007).
66. Schaller BJ, Modo M, Buchfelder M. Molecular imaging of brain tumors: a bridge between clinical and molecular medicine? Mol. Imaging Biol. 9(2), 60-71 (2007). (Pubitemid 46336220)
67. Liu CH, Kim YR, Ren JQ, Eichler F, Rosen BR, Liu PK. Imaging cerebral gene transcripts in live animals. J. Neurosci. 27(3), 713-722 (2007). (Pubitemid 46143775)